News

Upadacitinib headed to Phase 3 testing in SLE

Treatment with upadacitinib led to a significant reduction in disease activity for people with moderate-to-severe systemic lupus erythematosus (SLE) in a Phase 2 clinical trial, according to top-line results announced by its developer, AbbVie. Based on these positive results, AbbVie now is planning to advance upadacitinib to Phase 3 clinical…

Organ damage in SLE is linked to cognitive dysfunction

Organ damage is associated with a 1.49-times higher odds of having severe cognitive dysfunction in people with systemic lupus erythematosus (SLE), a new study reports. Organ damage was also associated with worse performance in multiple neuropsychological domains, such as working memory, processing speed, and complex attention. By contrast, the…

Enzyme tied to inflammatory immune cell activity in lupus

An enzyme called fumarate hydratase is involved in the control of the inflammatory activity of macrophages, a type of immune cell with a central role in driving inflammatory disorders like lupus, researchers report. “No-one has made a link from Fumarate Hydratase to inflammatory macrophages before and we feel that…

Rezpeg tamps down disease activity; fails to meet ISLAND primary goal

A middle dose of rezpegaldesleukin, an experimental medicine being developed by Nektar Therapeutics, led to clinically meaningful gains in measures of disease activity in people with systemic lupus erythematosus (SLE). That’s according to top-line data from ISLAND (NCT04433585), a Phase 2 clinical study that evaluated how safe…